Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05875701 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines
A Phase 3 study, sponsored by Novavax.
- Completed
- Registry status
- Phase 3
- Development phase
- 147
- Enrollment target
NCT05875701: Completed Phase 3 study, sponsored by Novavax.
NCT05875701 is a Phase 3 study that has completed, run by Novavax. The registered enrollment target is 147 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05875701, a Phase 3 study, has completed, sponsored by Novavax.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 147 participants
- Enrollment target
Study Summary
This is an open-label Phase 3 study evaluating the immunogenicity and safety of Novavax vaccine(s) with Matrix-M™ adjuvant (ancestral strain NVX-CoV2373 and an alternative strain and/or multivalent Novavax vaccine) as booster doses following a series of primary and booster doses of authorized/approved mRNA vaccines followed by a single booster dose of NVX-CoV2373 in the Novavax 2019nCoV-307 study (NCT05463068).
Primary Outcome
Neutralizing Antibody responses to ancestral strain Novavax vaccine (NVX-CoV2373) for the participants in the ancestral strain NVX-2373 group and NVX-CoV2540 group at Day 29
Interventions
- BIOLOGICAL NVX-CoV2373
- BIOLOGICAL SARS-CoV-2 rS antigen/Matrix-M Adjuvant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2023-03-28 |
| Est. Completion | 2023-11-11 |
| Phase | Phase 3 |
What the finished NCT05875701 record still lists
NCT05875701 is an interventional study that assigns participants to a tested intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which NVX-CoV2373 is the first listed.
NCT05875701 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05875701 about?
NCT05875701 is a clinical study titled "Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines". This is an open-label Phase 3 study evaluating the immunogenicity and safety of Novavax vaccine(s) with Matrix-M™ adjuvant (ancestral strain NVX-CoV2373 and an alternative strain and/or multivalent Novavax vaccine) as booster doses following a series of primary and booster doses of authorized/approv...
What is the current status of trial NCT05875701?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 147 participants. The study started on 2023-03-28. Estimated completion is 2023-11-11.
What interventions are being tested in trial NCT05875701?
The interventions under investigation include: NVX-CoV2373 (BIOLOGICAL), SARS-CoV-2 rS antigen/Matrix-M Adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT05875701?
This trial is sponsored by Novavax, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05875701's enrollment target sits among peer trials
147 1550th of 2000 higher than 450 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04396613 · 147 participants · NA
Wound Closure Techniques in Primary Spine Surgery
- NCT04851119 · 147 participants · Phase 1
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NCT05523947 · 147 participants · Phase 1
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- NCT06121843 · 147 participants · Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI